Skip to content
Biodatica
Start free

Iovance Biotherapeutics, Inc.

Gilbert, Arizona

OncologyPhase IIListed · IOVA

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

3w agoTrial registeredJun 26, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Momentum 91 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Mar 11, 2025

    Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma · RECRUITING · sponsor: Iovance Biotherapeutics, Inc. · A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

    ClinicalTrials.gov · NCT06940739 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Jul 20, 2022

    Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · RECRUITING · sponsor: Iovance Biotherapeutics, Inc. · A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

    ClinicalTrials.gov · NCT05361174 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    May 7, 2021

    Metastatic Non Small Cell Lung Cancer · RECRUITING · sponsor: Iovance Biotherapeutics, Inc. · Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

    ClinicalTrials.gov · NCT04614103 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources